Nautilus Biotechnology, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Nautilus Biotechnology, Inc. reported Cash And Cash Equivalents At Carrying Value of $12.39 million for the year ending 2025.

  • Nautilus Biotechnology, Inc. showed a decrease of -55.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Nautilus Biotechnology, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2020 to 2025), Nautilus Biotechnology, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 66.2%.
  • Historical annual values: Fiscal year 2025: $12.39 million | Fiscal year 2024: $27.65 million | Fiscal year 2023: $19.40 million | Fiscal year 2022: $114.52 million | Fiscal year 2021: $185.62 million | Fiscal year 2020: $36.61 million.
  • Data sourced from SEC EDGAR public filings as of June 24, 2026.

Last verified: